Eton Pharmaceuticals：FDA 核准 DESMODA（去氨加壓素）口服溶液

FDA 於 2026 年 2 月 25 日核准 DESMODA（醋酸去氨加壓素）口服溶液的 NDA。此核准涵蓋所有年齡患者的中樞性尿崩症／AVP-D 的抗利尿替代療法。該產品現已獲准在美國上市銷售。

關鍵事實

申報時間: 2026年2月25日下午07:18
事件: FDA 核准
方向: 正面
公司: ETONEton Pharmaceuticals
資產: desmopressin acetate
來源: SEC 8-K
可信度: 有出處

來源摘錄

eton20260223_8k.htm false 0001710340 0001710340 2026-02-25 2026-02-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 25, 2026 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) File Number) Identification Number) 21925 W. Field Parkway, Suite 235 Deer Park , Illinois 60010 -7278 (Address of principal executive offices) (Zip code) ( 847 ) 787-7361 (Registrant ’ s telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simul

SEC 8-K